CDKN1B Gene Multiple Endocrine Neoplasia Type 4 NGS Genetic DNA Test
Comprehensive Genetic Screening for MEN4 Cancer Risk
The CDKN1B Gene Multiple Endocrine Neoplasia Type 4 NGS Genetic DNA Test represents a breakthrough in hereditary cancer risk assessment. This advanced genetic screening utilizes Next-Generation Sequencing (NGS) technology to identify mutations in the CDKN1B gene, which are directly associated with Multiple Endocrine Neoplasia Type 4 (MEN4). MEN4 is a rare autosomal dominant cancer syndrome characterized by the development of tumors in multiple endocrine organs throughout the body.
What Does This Test Detect?
This comprehensive genetic analysis specifically targets the CDKN1B gene, which encodes the p27 protein – a critical tumor suppressor that regulates cell cycle progression. The test identifies:
- Pathogenic variants and mutations in the CDKN1B gene
- Single nucleotide polymorphisms (SNPs) associated with MEN4
- Insertions, deletions, and copy number variations
- Novel genetic alterations affecting p27 protein function
- Inherited mutations that significantly increase cancer susceptibility
Who Should Consider This Test?
This genetic screening is particularly important for individuals with:
- Personal history of multiple endocrine tumors
- Family history of MEN4 or related endocrine cancers
- Unexplained parathyroid adenomas or hyperparathyroidism
- Pituitary tumors without clear etiology
- Multiple endocrine gland involvement at young age
- Relatives of individuals with confirmed CDKN1B mutations
- Unexplained endocrine neoplasms in multiple family members
Key Symptoms and Clinical Indications
Patients experiencing the following symptoms should consider genetic testing:
- Recurrent kidney stones or bone pain (hyperparathyroidism)
- Vision changes or headaches (pituitary tumors)
- Hormonal imbalances affecting growth or metabolism
- Unexplained weight changes and fatigue
- Multiple endocrine-related health issues
- Early-onset endocrine disorders
Benefits of CDKN1B Genetic Testing
Proactive Cancer Risk Management
Early detection of CDKN1B mutations enables:
- Personalized cancer surveillance and screening protocols
- Timely intervention and preventive measures
- Informed family planning and genetic counseling
- Targeted monitoring for specific endocrine cancers
- Reduced anxiety through definitive genetic information
Clinical Advantages
- Comprehensive risk assessment for multiple endocrine cancers
- Guidance for appropriate medical management strategies
- Opportunity for early tumor detection and treatment
- Family-wide implications for cancer prevention
- Evidence-based decision making for healthcare providers
Understanding Your Test Results
Positive Result Interpretation
A positive result indicates the presence of a pathogenic CDKN1B mutation:
- Confirms increased risk for MEN4-associated cancers
- Requires implementation of enhanced surveillance protocols
- Necessitates genetic counseling for family members
- May influence treatment decisions for existing conditions
- Provides opportunity for preventive interventions
Negative Result Interpretation
A negative result suggests:
- No detected CDKN1B mutation associated with MEN4
- Significantly reduced hereditary cancer risk
- Standard cancer screening recommendations may apply
- Possible consideration of alternative genetic testing
- Reassurance for family cancer risk concerns
Variant of Uncertain Significance (VUS)
Some results may identify genetic changes with unclear clinical significance:
- Requires ongoing monitoring and research updates
- May warrant additional family member testing
- Should be interpreted with genetic counseling guidance
- Periodic re-evaluation as scientific knowledge advances
Test Details and Pricing
| Test Component | Details |
|---|---|
| Test Name | CDKN1B Gene Multiple Endocrine Neoplasia Type 4 NGS Genetic DNA Test |
| Regular Price | $700 USD |
| Discount Price | $500 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood or Extracted DNA or One drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) Technology |
| Specialty | Oncologist, Genetics Department |
Pre-Test Requirements
Before scheduling your CDKN1B genetic test, please ensure:
- Complete clinical history documentation
- Genetic counseling session to discuss implications
- Family pedigree chart creation for affected relatives
- Understanding of potential results and their meaning
- Informed consent process completion
Nationwide Availability
GGC DNA provides comprehensive genetic testing services across the United States. We have conveniently located branches in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art laboratories ensure accurate and reliable results for patients nationwide.
Take Control of Your Genetic Health Today
Don’t wait to understand your hereditary cancer risk. The CDKN1B Gene Multiple Endocrine Neoplasia Type 4 NGS Genetic DNA Test provides crucial information that can guide your healthcare decisions and potentially save lives through early detection and prevention.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic counseling session and book your test. Our genetic specialists are ready to help you navigate your cancer risk assessment and provide the comprehensive care you deserve.
Take the first step toward proactive cancer prevention and personalized healthcare management. Your genetic information is powerful – unlock its potential with GGC DNA’s advanced CDKN1B testing technology.
